StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback